Stanley L Liauw

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4646236/stanley-l-liauw-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126 60 3,805 27 h-index g-index citations papers 4,447 3.2 4.99 133 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
126	Hematuria Following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Follow-Up <i>Journal of Urology</i> , 2022 , 101097JU000000000002443	2.5	
125	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels Annals of Surgical Oncology, 2022, 1	3.1	1
124	Reply by Authors <i>Journal of Urology</i> , 2022 , 101097JU0000000000244302	2.5	
123	The Clinical Cell-Cycle Risk (CCR) score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 ,	4	1
122	A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. <i>Cancer</i> , 2021 , 127, 2631-2640	6.4	O
121	Goals of care discussions: perceptions of radiation and medical oncologists. <i>Supportive Care in Cancer</i> , 2021 , 29, 7279-7288	3.9	O
120	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 953-963	4	5
119	Comfort Level of US Radiation Oncology Graduates: Assessment of Transition to Independent Clinical Practice. <i>Journal of Cancer Education</i> , 2021 , 36, 278-283	1.8	3
118	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy <i>Journal of Clinical Oncology</i> , 2021 , 39, 195-195	2.2	
117	Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status. <i>Seminars in Radiation Oncology</i> , 2021 , 31, 349-360	5.5	2
116	Circulating tumor-tissue modified HPV DNA analysis for molecular disease monitoring after chemoradiation for anal squamous cell carcinoma: a case report <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 3155-3162	2.8	1
115	Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. <i>Cancer Medicine</i> , 2020 , 9, 4667-4675	4.8	4
114	Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments. <i>Journal of Applied Clinical Medical Physics</i> , 2020 , 21, 184-191	2.3	5
113	PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 600.e1-600.e8	2.8	3
112	A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. <i>Journal of Gastrointestinal Oncology</i> , 2020 , 11, 1399-1407	2.8	2
111	A prospective study evaluating oral-only hormonal therapy with radiation for intermediate or high-risk prostate cancer in men age []*0 years or with moderate comorbidity <i>Journal of Clinical Oncology</i> , 2020 , 38, 303-303	2.2	
110	F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. <i>Practical Radiation Oncology</i> , 2020 , 10, 354-362	2.8	5

109	Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. Journal of the National Cancer Institute, 2020 , 112, 847-854	9.7	14
108	Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa081	4.6	
107	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019 , 19, 572	4.8	2
106	Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. <i>European Urology</i> , 2019 , 76, 686-692	10.2	8
105	Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sary syndrome. <i>British Journal of Haematology</i> , 2019 , 186, 377-379	4.5	4
104	Regional Influence of Radiation Oncology Residency Training on Job Securement over Two Time Periods. <i>Cureus</i> , 2019 , 11, e4495	1.2	
103	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019 , 202, 272-281	2.5	70
102	Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 382-390	2.7	1
101	Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e12-e18	3.3	3
100	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018 , 4, e175230	13.4	49
99	Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. <i>Journal of Surgical Education</i> , 2018 , 75, 434-441	3.4	1
98	Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 471.e11-471.e18	2.8	4
97	Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. <i>PLoS ONE</i> , 2018 , 13, e0194234	3.7	4
96	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis <i>Journal of Clinical Oncology</i> , 2018 , 36, 24-24	2.2	
95	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018 , 74, 99-106	10.2	18
94	Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 304-313	4	10
93	Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines. <i>Advances in Radiation Oncology</i> , 2018 , 3, 339-345	3.3	4
92	High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir D.2 to Select Men for Short-term Hormonal Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 348-352	2.7	3

91	Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 612-620	2.7	9
90	Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 643-650	4	
89	Radiation oncology residency selection: A postgraduate evaluation of factor importance and survey of variables associated with job securement. <i>Practical Radiation Oncology</i> , 2017 , 7, 425-432	2.8	14
88	ACR Appropriateness Criteria Locally Advanced, High-Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 1-10	2.7	7
87	The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update. <i>Current Urology Reports</i> , 2017 , 18, 50	2.9	5
86	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. <i>Advances in Radiation Oncology</i> , 2017 , 2, 437-454	3.3	18
85	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2017 , 16, 266-276	2.4	22
84	Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. <i>Urologic Clinics of North America</i> , 2017 , 44, 597-609	2.9	О
83	A Pancreatic Predicament. International Journal of Radiation Oncology Biology Physics, 2017, 99, 296-29	74	5
82	Gastrointestinal Cancers: Timing Is Everything. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 1051-1058	4	
81	Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 306-312	4	19
80	External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 740-746	4	4
79	ACR Appropriateness Criteria external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. <i>Advances in Radiation Oncology</i> , 2017 , 2, 62-84	3.3	21
78	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy <i>Journal of Clinical Oncology</i> , 2017 , 35, 9-9	2.2	
77	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy <i>Journal of Clinical Oncology</i> , 2017 , 2017, 9-9	2.2	
76	External validation and optimization of international consensus clinical target volumes for adjuvant radiation in bladder cancer <i>Journal of Clinical Oncology</i> , 2017 , 35, 336-336	2.2	
75	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3648-3654	2.2	200
74	Gastrointestinal Cancers-Changing the Standard for Rectal Cancer and Establishing a New Standard for Liver Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 930-6	4	1

73	Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 416.	.e18-2	1 ¹⁵
72	A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. <i>Journal of the American College of Radiology</i> , 2016 , 13, 835-841.e1	3.5	7
71	ACR Appropriateness Criteria Renal Cell Carcinoma Staging. <i>Journal of the American College of Radiology</i> , 2016 , 13, 518-25	3.5	28
70	Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 1031-9	4	26
69	In Reply to Zaghloul. International Journal of Radiation Oncology Biology Physics, 2016, 95, 855	4	
68	Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. <i>Practical Radiation Oncology</i> , 2016 , 6, e179-e	<u>28</u> 5	6
67	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 1046-1053	4	34
66	The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. <i>Practical Radiation Oncology</i> , 2015 , 5, e223-e228	2.8	5
65	Image-guided radiation therapy for prostate cancer: A computed tomography-based assessment of fiducial marker migration between placement and 7 days. <i>Practical Radiation Oncology</i> , 2015 , 5, 241-7	2.8	8
64	Key New Studies in Gastric and Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 475-81	4	1
63	Management of Low-Stage Testicular Seminoma. <i>Urologic Clinics of North America</i> , 2015 , 42, 287-98	2.9	8
62	Randomized trials and new directions in gastrointestinal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 459-64	4	3
61	Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. <i>PLoS ONE</i> , 2015 , 10, e014	4₹ 7 39	9
60	The role of the radiation oncologist in goals-of-care discussions <i>Journal of Clinical Oncology</i> , 2015 , 33, 42-42	2.2	
59	Oncology scan-novel treatment strategies for gastrointestinal cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 699-703	4	4
58	Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. <i>PLoS ONE</i> , 2014 , 9, e82642	3.7	15
57	Considering the role of radiation therapy for gastrointestinal stromal tumor. <i>OncoTargets and Therapy</i> , 2014 , 7, 713-8	4.4	11
56	Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. <i>Cancer Medicine</i> , 2014 , 3, 954-61	4.8	14

55	Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 122-5	2.7	1
54	Herpes zoster and radiation therapy: what radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. <i>Practical Radiation Oncology</i> , 2014 , 4, 58-64	2.8	4
53	Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. <i>Urology</i> , 2013 , 81, 1196-201	1.6	22
52	Validation of normal tissue complication probability predictions in individual patient: late rectal toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 1103-9	4	4
51	Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 378-	8 ⁴ 4	59
50	Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy. Practical Radiation Oncology, 2013, 3, e1-e9	2.8	13
49	Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. <i>Practical Radiation Oncology</i> , 2013 , 3, 138-4	1 3 .8	15
48	New paradigms and future challenges in radiation oncology: an update of biological targets and technology. <i>Science Translational Medicine</i> , 2013 , 5, 173sr2	17.5	151
47	Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013 , 36, 589-95	2.7	71
46	Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. <i>Cancer</i> , 2013 , 119, 2807-14	6.4	17
45	Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. <i>OncoTargets and Therapy</i> , 2013 , 6, 1097-110	4.4	2
44	Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 235-41	4	80
43	High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 1473-9	4	10
42	Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: a report of total setup error, required PTV expansion, and dosimetric implications. <i>Radiotherapy and Oncology</i> , 2012 , 103, 270-4	5.3	21
41	Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. <i>Journal of Gastrointestinal Cancer</i> , 2012 , 43 Suppl 1, S202	-7 6	
40	Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. <i>Annals of Surgical Oncology</i> , 2012 , 19, 2471-6	3.1	18
39	Radiation dose B4 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. <i>Radiation Oncology</i> , 2012 , 7, 156	4.2	13
38	Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3540-4	2.2	83

(2009-2011)

37	Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 751-7	4	7
36	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. <i>Research and Reports in Urology</i> , 2011 , Volume 3, 95-104	1.3	
35	Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1022-8	4	8
34	External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 1080-6	4	33
33	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. <i>Open Access Journal of Urology</i> , 2011 , 3, 95-104		1
32	Radiotherapeutic strategies in the management of low-risk prostate cancer. <i>Scientific World Journal, The</i> , 2010 , 10, 1854-69	2.2	5
31	Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2653-9	2.2	129
30	Reply to H.W. Daniell and to L. Azoulay and S. Suissa. <i>Journal of Clinical Oncology</i> , 2010 , 28, e645-e646	2.2	
29	The role of radiotherapy in locally advanced pancreatic carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 437-47	24.2	32
28	A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 619-23	2.7	12
27	External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 106	5 0 -5	29
26	Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis. <i>Brachytherapy</i> , 2010 , 9, 131-6	2.4	15
25	The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. <i>Cancer</i> , 2010 , 116, 1820-6	6.4	47
24	External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 755-60	4	56
23	Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 125	5 -3 0	13
22	Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 168-7	7 2 .7	22
21	Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. <i>Technology in Cancer Research and Treatment</i> , 2009 , 8, 201-6	2.7	19
20	Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 38-46		11

19	Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. <i>Cancer</i> , 2009 , 115, 1784-90	6.4	13
18	The use of capecitabine in the combined-modality therapy for rectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 99-104	3.8	3
17	A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. <i>Urology</i> , 2008 , 72, 1298-302; discussion 1302-4	1.6	86
16	Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 375-8	2.7	36
15	Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection?. <i>Cancer</i> , 2008 , 112, 1076-82	6.4	42
14	Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1316-21	4	10
13	Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. <i>Head and Neck</i> , 2007 , 29, 715-9	4.2	20
12	Radiotherapy after subtotally resected or recurrent ganglioglioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 244-7	4	43
11	Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2035-41	2.2	694
10	Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4581-6	2.2	218
9	The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. <i>Clinical Medicine and Research</i> , 2007 , 5, 123-31	1.4	6
8	Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1421-7	2.2	136
7	Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 669-73	4	95
6	Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: incomplete radiographic response does not necessarily indicate failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 1017-21	4	5
5	Whole-abdomen radiotherapy for non-Hodgkinß lymphoma using twice-daily fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 1440-5	4	2
4	The effect of intravenous contrast on intensity-modulated radiation therapy dose calculations for head and neck cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 456-9	2.7	23
3	Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 1325-32	27.4	503
2	Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. <i>Cancer</i> , 2004 , 100, 920-8	6.4	48

Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. *Urology*, **2003**, 61, 1204-10

1.6 48